Patent ID: 7235547

Claim:
A method of treating acute or chronic neurological disorders comprising administering to a mammal in need thereof a pharmaceutical composition comprising a therapeutically effective amount of an AChE inhibitor selected from the group consisting of donepezil, rivastigmine, metrifonate, galantamine, physostigmine, tacrine, fordine, phenserine, citicoline and ganstigmine and an mGluR2 antagonist of formula I wherein X is a single bond or an ethynediyl group; Y is —CH═ or ═N—; R 1 is, in case X is a single bond, selected from hydrogen, cyano, halogen, (C 1 –C 7 )-alkyl, (C 1 –C 7 )-alkoxy, fluoro-(C 1 –C 7 )-alkyl, fluoro-(C 1 –C 7 )-alkoxy, pyrrol-1-yl, unsubstituted phenyl, and phenyl substituted by one or two substituents selected from the group consisting of halogen, (C 1 –C 7 )-alkyl and fluoro-(C 1 –C 7 )-alkyl; or R 1 is, in case X is an ethynediyl group, selected from unsubstituted phenyl, and phenyl substituted by one or two substituents selected from the group consisting of halogen, (C 1 –C 7 )-alkyl and fluoro-(C 1 –C 7 )-alkyl; R 2 is selected from hydrogen, (C 1 –C 7 )-alkyl, (C 2 –C 7 )-alkenyl, (C 1 –C 7 )-alkoxy, halogen, —NR′R″, pyrrolidin-1-yl, piperidin-1-yl, morpholine-4-yl, fluoro-(C 1 –C 7 )-alkyl, fluoro-(C 1 –C 7 )-alkoxy, and (C 1 –C 7 )-alkoxy-(ethoxy) m ; wherein m is 1, 2, 3 or 4; and R 3 is a six-membered aromatic heterocycle ring containing 1 to 3 nitrogen atoms or a pyridine-N-oxide, which ring is unsubstituted or substituted by one or two substituents selected from the group consisting of halogen, fluoro-(C 1 –C 7 )-alkyl, fluoro-(C 1 –C 7 )-alkoxy, cyano, amino, (C 1 –C 7 )-alkylamino, (C 1 –C 7 )-dialkylamino, (C 1 –C 7 )-alkoxy-(C 1 –C 7 )-alkylamino, (C 1 –C 7 )-hydroxy-(C 1 –C 7 )-alkylamino, —(CH 2 ) n —C(O)—OR″, —(CH 2 ) n —C(O)—NR′R″, —(CH 2 ) n —SO 2 —NR′R″, —(CH 2 ) n —C(NH 2 )═NR″, hydroxy, (C 1 –C 7 )-alkoxy, (C 1 –C 7 )-alkylthio, C 3 –C 7 -cycloalkyl, (C 1 –C 7 )-alkyl, and (C 1 –C 7 )-alkyl substituted by a group consisting of fluoro, —NR′R″, hydroxy, (C 1 –C 7 )-alkoxy, pyrrolidin-1-yl, azetidin-1-yl, cyano and carbamoyloxy, wherein n is 0, 1, 2, 3 or 4; and R′ and R″ are each independently selected from hydrogen, (C 1 –C 7 )-alkyl and (C 3 –C 7 )-cycloalkyl; or a pharmaceutically acceptable salt thereof.